

**Shield Therapeutics plc
("Shield" or the "Company" or the "Group")**

Total Voting Rights Update

London, UK, 28 February 2023:Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer® (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 585,669,777 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Shield Therapeutics plc

Greg Madison, CEO
Hans-Peter Rudolf, CFO

www.shieldtherapeutics.com

+44 (0) 191 511 8500

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Oliver Duckworth

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks

+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR

Lianne Applegarth/Alice Woodings

+44 (0)20 7933 8780 or shield@walbrookpr.com

Investor Contact (US Advisor)

LifeSci Advisors, LLC

John Mullaly

+1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVREDLFLXLLBBBD